Diurnal is an innovative pharmaceutical company that creates high-value therapeutics using proprietary formulations and novel physiological treatment regimes of approved drugs.
Diurnal products address the major unmet needs of endocrine (hormone) treatments for patients and can be rapidly taken through clinical development to key clinical value points that will underpin commercialisation of these differentiated drug products.
Diurnal's lead product is Chronocort - a delayed sustained release formulation of hydrocortisone for the treatment of congenital adrenal hyperplaisia and adrenal insufficiency - both orphan drug diseases. Chronocort entered Phase 1 clinical testing in April 2010 and is expected to be on the market in late 2014.
Specialties
Physiological Hormone Replacement
